Hoyin Chu

Hoyin Chu

Computational Biologist with background in computer science and mathematics. Interested in the application and development of computational methods to answer questions in cancer genomics.

Publications

This page features full-length papers where I am one of the authors. For conference abstracts see Abstracts

You can also find my papers on my Google Scholar profile.

# Denotes equal contributions

FIRST / CO-FIRST AUTHOR

  1. Arthur Chow#, Hoyin Chu#, et al. (2025) Sequence and structural determinants of efficacious de novo chimeric antigen receptors. bioRxiv. DOI: https://doi.org/10.64898/2025.12.12.694033

  2. Mohammed Al-Jumaan#, Hoyin Chu#, et al. (2023) Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients. Genome Medicine. DOI: https://doi.org/10.1186/s13073-023-01220-4

  3. Abdullah Al-Sulaiman#, Hoyin Chu#, et al. (2023) Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients. Pharmacogenomics. DOI: https://doi.org/10.2217/pgs-2023-0029

  4. Hoyin Chu, et al. (2023) Using Association Rules to Understand the Risk of Adverse Pregnancy Outcomes in a Diverse Population, Pacific Symposium on Biocomputing. DOI: https://doi.org/10.1142/9789811270611_0020

  5. Kymberleigh A. Pagel#, Hoyin Chu#, et al. (2022) The influence of genetic predisposition and physical activity on risk of Gestational Diabetes Mellitus in the nuMoM2b cohort. JAMA Network Open. DOI: https://doi.org/10.1001/jamanetworkopen.2022.29158

CO-AUTHOR

  1. Maria Caterina Rotiroti, Aidan M Tousley, Hoyin Chu, et al. (2025) Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy. Nature Cancer. DOI: https://doi.org/10.1038/s43018-025-01056-4

  2. Mark B Leick, …, Hoyin Chu, et al. (2025) Genomic correlates of clinical CAR-T cell activity. medRxiv. DOI: https://doi.org/10.1101/2025.10.08.25337584

  3. Alexandre Pellan Cheng, …, Hoyin Chu, et al. (2025) Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling. Nature Methods. DOI: https://doi.org/10.1038/s41592-025-02648-9

  4. Romualdo Barroso-Sousa, …, Hoyin Chu, et al. (2025) Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS). Nature Communications. DOI: https://doi.org/10.1038/s41467-025-59695-1

  5. Seung Hun Han, Sabrina Y. Camp, Hoyin Chu, et al. (2024) Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science. DOI: https://doi.org/10.1016/j.euros.2024.02.006.

  6. The Critical Assessment of Genome Interpretation Consortium, including Hoyin Chu. (2024) CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods. Genome Biology. DOI: https://doi.org/10.1186/s13059-023-03113-6

  7. Riaz Gillani, Sabrina Y. Camp, Seunghun Han, Jill K. Jones, Hoyin Chu, et al. (2022) Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. The American Journal of Human Genetics. DOI: https://doi.org/10.1016/j.ajhg.2022.04.007


Back to top
Last update: 2025-12-15